Characterisation of Non-Carbapenemase-Producing Carbapenem-Resistant Klebsiella pneumoniae Based on Their Clinical and Molecular Profile in Malaysia.
Yee Qing LeeSasheela Sri La Sri PonnampalavanarChong Chun WieRina KarunakaranKumutha Malar VellasamyKartini Abdul JabarZhi Xian KongMin Yi LauCindy Shuan Ju TehPublished in: Antibiotics (Basel, Switzerland) (2022)
Non-carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae (NC-CRKP) confers carbapenem resistance through a combination of chromosomal mutations and acquired non-carbapenemase resistance mechanisms. In this study, we aimed to evaluate the clinical and molecular profiles of NC-CRKP isolated from patients in a tertiary teaching hospital in Malaysia from January 2013 to October 2019. During the study period, 54 NC-CRKP-infected/colonised patients' isolates were obtained. Clinical parameters were assessed in 52 patients. The all-cause in-hospital mortality rate among NC-CRKP patients was 46.2% (24/52). Twenty-three (44.2%) patients were infected, while others were colonised. Based on the Charlson Comorbidity Index (CCI) score, 92.3% (48/52) of the infected/colonised patients had a score of ≥ 1. Resistance genes found among the 54 NC-CRKP isolates were bla TEM , bla SHV , bla CTX-M , bla OXA , and bla DHA . Porin loss was detected in 25/54 (46.3%) strains. None of the isolated strains conferred carbapenem resistance through the efflux pumps system. In conclusion, only 25/54 (46.3%) NC-CRKP conferred carbapenem resistance through a combination of porin loss and the acquisition of non-carbapenemase resistance mechanisms. The carbapenem resistance mechanisms for the remaining strains (53.7%) should be further investigated as rapid identification and distinction of the NC-CRKP mechanisms enable optimal treatment and infection control efforts.
Keyphrases
- klebsiella pneumoniae
- end stage renal disease
- escherichia coli
- multidrug resistant
- ejection fraction
- newly diagnosed
- chronic kidney disease
- acinetobacter baumannii
- peritoneal dialysis
- drug resistant
- gram negative
- pseudomonas aeruginosa
- transcription factor
- patient reported outcomes
- quality improvement
- genome wide
- high speed
- replacement therapy